

PHARMACEUTICAL TURNOVER
Three months ended 30th September 2006

	Total			USA			Europe			International		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
RESPIRATORY	1,185	(1)	(4)	593	(4)	(9)	399	4	3	193	3	(2)
<i>Seretide/Advair</i>	813	14	10	464	17	11	271	12	10	78	7	5
<i>Flixotide/Flovent</i>	145	(1)	(4)	64	3	(2)	39	(7)	(7)	42	-	(5)
<i>Serevent</i>	69	(10)	(13)	20	(16)	(20)	35	(11)	(8)	14	-	(13)
<i>Flixonase/Flonase</i>	64	(59)	(61)	39	(70)	(72)	10	(29)	(29)	15	23	15
CENTRAL NERVOUS	913	18	13	661	34	28	142	(16)	(17)	110	-	(7)
<i>Seroxat/Paxil</i>	137	4	(3)	33	62	57	35	(27)	(27)	69	7	(4)
<i>Paxil IR</i>	103	(8)	(13)	2	100	100	35	(29)	(29)	66	6	(3)
<i>Paxil CR</i>	34	61	48	31	60	55	-	-	-	3	25	(25)
<i>Wellbutrin</i>	234	27	22	229	28	22	1	-	-	4	(20)	(20)
<i>Wellbutrin IR, SR</i>	26	17	13	22	21	16	1	-	-	3	(25)	(25)
<i>Wellbutrin XL</i>	208	28	23	207	29	23	-	-	-	1	-	-
<i>Imigran/Imitrex</i>	180	4	-	144	15	10	26	(28)	(28)	10	(15)	(23)
<i>Lamictal</i>	257	27	22	201	43	39	42	(16)	(16)	14	7	(7)
<i>Requip</i>	70	71	67	46	>100	100	21	24	24	3	50	50
ANTI-VIRALS	703	9	6	339	6	2	218	14	13	146	11	6
HIV	363	(6)	(9)	168	(11)	(15)	149	-	(2)	46	(4)	(6)
<i>Combivir</i>	125	(12)	(15)	57	(15)	(20)	52	(9)	(9)	16	(5)	(16)
<i>Trizivir</i>	63	(16)	(18)	34	(19)	(21)	27	(10)	(10)	2	(25)	(50)
<i>Eпивir</i>	46	(25)	(29)	16	(23)	(27)	21	(33)	(30)	9	(8)	(31)
<i>Ziagen</i>	28	(12)	(15)	11	(8)	(15)	10	(23)	(23)	7	-	-
<i>Agenerase, Lexiva</i>	32	3	3	18	(10)	(10)	12	33	33	2	-	-
<i>Epzicom/Kivexa</i>	63	88	85	31	38	29	26	>100	>100	6	>100	>100
Herpes	242	21	15	160	35	30	36	3	3	46	-	(12)
<i>Valtrex</i>	215	26	20	158	36	31	28	12	12	29	-	(12)
<i>Zovirax</i>	27	(6)	(13)	2	-	-	8	(20)	(20)	17	-	(11)
<i>Zeffix</i>	42	16	14	4	-	33	6	50	50	32	13	7
<i>Relenza</i>	30	-	-	-	-	-	24	>100	>100	6	>100	>100
METABOLIC	438	16	11	289	15	8	64	30	28	85	10	8
<i>Avandia</i>	323	13	8	242	14	8	30	7	7	51	16	13
<i>Avandamet</i>	44	(21)	(23)	13	(64)	(67)	25	100	92	6	-	20
<i>Avandaryl</i>	11	-	-	10	-	-	-	-	-	1	-	-
<i>Bonviva/Boniva</i>	27	>100	>100	24	>100	>100	3	>100	>100	-	-	-
VACCINES	412	5	3	130	8	6	169	6	4	113	2	(1)
<i>Hepatitis</i>	114	(2)	(5)	39	-	(9)	54	(5)	(8)	21	6	17
<i>Infanrix/Pediarix</i>	122	6	3	45	(4)	(6)	65	16	16	12	-	(14)
<i>Boostrix</i>	18	64	64	14	75	75	3	50	50	1	-	-
CARDIOVASCULAR AND UROGENITAL	406	23	18	269	37	31	96	(6)	(7)	41	23	17
<i>Coreg</i>	195	32	27	193	32	26	-	-	-	2	100	100
<i>Levitra</i>	11	22	22	11	71	57	-	-	-	-	-	-
<i>Avodart</i>	57	61	58	37	85	85	17	21	21	3	100	50
<i>Arixtra</i>	13	100	86	7	>100	>100	6	>100	>100	-	-	-
<i>Fraxiparine</i>	49	2	-	-	-	-	44	5	2	5	(17)	(17)
ANTI-BACTERIALS	311	(8)	(11)	52	(2)	(7)	135	(13)	(14)	124	(5)	(9)
<i>Augmentin</i>	121	(15)	(19)	20	(28)	(31)	54	(21)	(21)	47	(2)	(10)
<i>Zinnat/Ceftin</i>	35	(10)	(15)	3	-	50	16	(16)	(16)	16	(5)	(20)
ONCOLOGY AND EMESIS	279	11	6	223	18	12	37	(8)	(8)	19	(13)	(17)
<i>Zofran</i>	223	8	4	185	16	11	25	(10)	(14)	13	(26)	(32)
<i>Hycamtin</i>	28	12	8	17	-	(6)	10	29	43	1	100	-
OTHER	229	(7)	(10)	18	6	-	61	(18)	(20)	150	(2)	(7)
<i>Zantac</i>	51	(11)	(16)	16	7	7	11	(31)	(31)	24	(10)	(20)
	4,876	7	4	2,574	14	9	1,321	-	(1)	981	3	(2)

Pharmaceutical turnover includes co-promotion income.

PHARMACEUTICAL TURNOVER
Nine months ended 30th September 2006

	Total			USA			Europe			International		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
RESPIRATORY	3,726	1	2	1,845	(2)	-	1,264	3	3	617	6	7
<i>Seretide/Advair</i>	2,451	13	14	1,377	13	15	840	11	11	234	12	16
<i>Flixotide/Flovent</i>	487	4	5	219	13	15	131	(6)	(6)	137	1	1
<i>Serevent</i>	217	(11)	(11)	64	(16)	(15)	107	(12)	(12)	46	2	(2)
<i>Flixonase/Flonase</i>	263	(46)	(46)	167	(55)	(55)	40	(15)	(15)	56	(17)	(15)
CENTRAL NERVOUS	2,727	16	17	1,928	29	32	458	(15)	(15)	341	5	3
<i>Seroxat/Paxil</i>	457	1	-	126	23	25	114	(22)	(22)	217	8	4
<i>Paxil IR</i>	335	(6)	(8)	16	(11)	(11)	114	(22)	(22)	205	6	2
<i>Paxil CR</i>	122	32	34	110	30	33	-	-	-	12	50	50
<i>Wellbutrin</i>	688	30	32	674	30	32	2	100	100	12	20	20
<i>Wellbutrin IR, SR</i>	77	12	13	67	10	12	2	100	100	8	14	14
<i>Wellbutrin XL</i>	611	32	35	607	32	35	-	-	-	4	33	33
<i>Imigran/Imitrex</i>	537	4	6	413	11	13	93	(12)	(12)	31	(16)	(16)
<i>Lamictal</i>	739	17	19	561	36	39	136	(22)	(22)	42	2	2
<i>Requip</i>	192	79	81	124	>100	>100	60	22	22	8	33	33
ANTI-VIRALS	2,121	10	12	1,021	7	9	645	11	12	455	18	18
HIV	1,155	-	1	532	(7)	(6)	475	5	5	148	10	12
<i>Combivir</i>	409	(7)	(6)	182	(14)	(13)	169	(2)	(2)	58	8	9
<i>Trizivir</i>	207	(9)	(8)	109	(12)	(11)	88	(5)	(5)	10	(9)	(9)
<i>Eпивir</i>	159	(21)	(20)	54	(25)	(24)	72	(24)	(23)	33	(3)	(6)
<i>Ziagen</i>	89	(14)	(13)	36	(12)	(12)	31	(28)	(28)	22	17	22
<i>Agenerase, Lexiva</i>	97	20	23	55	8	10	36	50	50	6	-	20
<i>Epzicom/Kivexa</i>	172	>100	>100	92	60	61	68	>100	>100	12	>100	>100
Herpes	723	19	20	456	30	33	108	3	3	159	7	4
<i>Valtrex</i>	633	24	25	450	30	33	82	11	11	101	12	10
<i>Zovirax</i>	90	(5)	(7)	6	20	20	26	(16)	(16)	58	(2)	(5)
<i>Zeffix</i>	120	15	17	10	-	11	17	13	13	93	16	18
<i>Relenza</i>	54	>100	>100	1	-	-	39	>100	>100	14	>100	>100
METABOLIC	1,401	24	26	956	26	28	183	36	36	262	14	17
<i>Avandia</i>	1,075	22	24	822	24	26	95	14	14	158	17	23
<i>Avandamet</i>	136	4	5	54	(40)	(39)	65	>100	>100	17	33	42
<i>Avandaryl</i>	28	-	-	26	-	-	-	-	-	2	-	-
<i>Bonviva/Boniva</i>	61	>100	>100	54	>100	>100	7	>100	>100	-	-	-
VACCINES	1,165	19	20	303	23	25	509	20	20	353	15	17
<i>Hepatitis</i>	351	5	6	118	15	16	167	(1)	(1)	66	8	12
<i>Infanrix/Pediarix</i>	375	29	30	125	14	16	209	41	42	41	24	24
<i>Boostrix</i>	42	>100	>100	28	>100	>100	10	100	100	4	33	33
CARDIOVASCULAR AND UROGENITAL	1,215	24	26	791	42	44	294	(5)	(5)	130	22	23
<i>Coreg</i>	580	38	40	575	38	40	-	-	-	5	25	25
<i>Levitra</i>	31	-	3	29	12	12	1	(67)	(67)	1	(100)	-
<i>Avodart</i>	155	70	72	95	>100	>100	50	25	25	10	67	67
<i>Arixtra</i>	37	>100	>100	20	>100	>100	16	>100	>100	1	-	-
<i>Fraxiparine</i>	156	(1)	-	-	-	-	135	2	2	21	(13)	(9)
ANTI-BACTERIALS	1,015	(10)	(9)	160	(16)	(14)	464	(13)	(13)	391	(2)	(1)
<i>Augmentin</i>	425	(15)	(14)	69	(35)	(34)	201	(15)	(15)	155	(1)	(1)
<i>Zinnat/Ceftin</i>	122	(15)	(15)	9	33	50	60	(28)	(28)	53	(2)	(2)
ONCOLOGY AND EMESIS	856	13	15	674	20	22	120	(4)	(4)	62	(8)	(6)
<i>Zofran</i>	682	11	12	549	17	19	86	(9)	(9)	47	(13)	(13)
<i>Hycamtin</i>	85	14	15	54	8	10	26	19	24	5	50	25
OTHER	716	(7)	(7)	65	24	27	183	(22)	(22)	468	(3)	(3)
<i>Zantac</i>	177	(1)	(2)	56	34	37	39	(17)	(17)	82	(9)	(11)
	14,942	9	10	7,743	16	18	4,120	-	-	3,079	7	7

Pharmaceutical turnover includes co-promotion income.

INCOME STATEMENT
Three months ended 30th September 2006

	Q3 2006 £m	Q3 2005 £m	Growth CER%	£%
Turnover:				
Pharmaceuticals	4,876	4,709	7	4
Consumer Healthcare	766	762	4	1
TURNOVER	5,642	5,471	7	3
Cost of sales	(1,222)	(1,184)	5	3
Gross profit	4,420	4,287	7	3
Selling, general and administration	(1,617)	(1,884)	(10)	(14)
Research and development	(871)	(803)	11	8
Other operating income	91	183		
Operating profit:				
Pharmaceuticals	1,842	1,553	24	19
Consumer Healthcare	181	230	(19)	(21)
OPERATING PROFIT	2,023	1,783	19	13
Finance income	64	67		
Finance expense	(81)	(113)		
Share of after tax profits of associates and joint ventures	16	16		
PROFIT BEFORE TAXATION	2,022	1,753	21	15
Taxation	(596)	(500)		
<i>Tax rate %</i>	<i>29.5%</i>	<i>28.5%</i>		
PROFIT AFTER TAXATION FOR THE PERIOD	1,426	1,253	19	14
Profit attributable to minority interests	35	46		
Profit attributable to shareholders	1,391	1,207		
	1,426	1,253		
EARNINGS PER SHARE	24.7p	21.3p	21	16
Diluted earnings per share	24.4p	21.1p		

INCOME STATEMENT
Nine months ended 30th September 2006

	9 months 2006 £m	9 months 2005 £m	Growth CER%	£%
Turnover:				
Pharmaceuticals	14,942	13,553	9	10
Consumer Healthcare	2,324	2,200	5	6
TURNOVER	17,266	15,753	9	10
Cost of sales	(3,565)	(3,466)	2	3
Gross profit	13,701	12,287	10	12
Selling, general and administration	(5,323)	(5,210)	1	2
Research and development	(2,477)	(2,168)	13	14
Other operating income	207	332		
Operating profit:				
Pharmaceuticals	5,624	4,719	18	19
Consumer Healthcare	484	522	(8)	(7)
OPERATING PROFIT	6,108	5,241	16	17
Finance income	204	172		
Finance expense	(266)	(326)		
Share of after tax profits of associates and joint ventures	43	39		
PROFIT BEFORE TAXATION	6,089	5,126	18	19
Taxation	(1,796)	(1,461)		
<i>Tax rate %</i>	<i>29.5%</i>	<i>28.5%</i>		
PROFIT AFTER TAXATION FOR THE PERIOD	4,293	3,665	16	17
Profit attributable to minority interests	85	98		
Profit attributable to shareholders	4,208	3,567		
	4,293	3,665		
EARNINGS PER SHARE	74.5p	62.8p	18	19
Diluted earnings per share	73.5p	62.3p		

CONSUMER HEALTHCARE TURNOVER
Three months ended 30th September 2006

	Q2 2006 £m	Growth CER%	£%
Over-the-counter medicines	348	4	-
Analgesics	91	1	(3)
Dermatological	37	12	9
Gastrointestinal	61	(2)	(5)
Respiratory tract	42	22	17
Smoking control	73	(6)	(10)
Natural wellness support	30	(3)	(3)
Oral care	240	-	(3)
Nutritional healthcare	178	8	6
Total	766	4	1

CONSUMER HEALTHCARE TURNOVER
Nine months ended 30th September 2006

	Q2 2006 £m	Growth CER%	£%
Over-the-counter medicines	1,087	4	5
Analgesics	285	6	6
Dermatological	122	-	2
Gastrointestinal	189	1	4
Respiratory tract	118	16	16
Smoking control	250	2	3
Natural wellness support	94	(4)	(3)
Oral care	735	5	5
Nutritional healthcare	502	8	8
Total	2,324	5	6